Tính hiệu quả
Tính hiệu quả
Tính an toàn
Tính an toàn
- RealGiDo confirms value of AFATINIB dose modification similar to that observed in RCTs
- Patterns of AEs with AFATINIB in real world compared to RCTs
Sự kiện
Sự kiện
- YATO||The 5th YATO 2023

Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1^st line choice in sequential therapy of NSCLC

Higher in-vitro sensitivity of common EGFR mutations to AFATINIB translates to improved tumor responses in NSCLC

Document ID: PC-VN-101464

28/06/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

PC-VN-101464
Production date: June 2021